Pulmonary Sarcoidosis
Section snippets
Clinical symptoms of pulmonary sarcoidosis
The clinical manifestations of sarcoidosis are heterogeneous and overlap with many infectious and noninfectious granulomatous disorders. Although the lung is involved in more than 90% of patients, multisystemic involvement is characteristic of the disease, and virtually any organ can be affected [1], [2], [3], [4]. In some patients, extrapulmonary manifestations are the presenting and predominant features. Recognition of extrapulmonary features of sarcoidosis is critical to ensure prompt
Fever
Sarcoidosis is an important cause of “fever of unknown origin” [11], [12], although fever is more common in tuberculosis, fungal infection, and some other granulomatous infections. Fever may occur in the early course of sarcoidosis, but fever that lasts longer than 6 weeks occurs in less than 5% of patients who have sarcoidosis [11], [12], [13], [14], [15], [16]. The fever of an early stage of sarcoidosis spontaneously remits within a few weeks in most patients [10]. Fever can be combined with
Clinical appearance of sarcoidosis
Clinical manifestations of sarcoidosis show various symptoms and signs depending on the organ involved. Commonly, sarcoidosis is the disease with an acute onset. In some patients, sarcoidosis is a chronic disease with an atypical, unusual onset, which clinically may represent a broad spectrum of any other infectious or noninfectious disease. Possible clinical manifestations of sarcoidosis are shown in Box 1.
Sarcoidosis of the airways: endobronchial sarcoidosis
The bronchial mucosa is often involved in sarcoidosis. In one study, 40% of patients with stage I and approximately 70% of patients with stages II and III had noncaseating granulomas in bronchial biopsy specimens [3]. Endobronchial sarcoidosis is commonly found as nodular elevation on the bronchial mucosa, with the nodules 2 to 3 mm in diameter. Uncommonly, there are gross mucosal abnormalities [19]. Rarely, granulomatous involvement may produce narrowing of bronchi with resulting atelectasis
Influence of clinical findings on prognosis of pulmonary sarcoidosis
Clinical manifestations of sarcoidosis may have some prognostic value. Löfgren's syndrome (manifested as BHL, erythema nodosum polyarthritis, and fever) in acute onset of sarcoidosis has excellent prognosis [6], [29], [30]. Patients have high rates of spontaneous remission. Clinical manifestations associated with poor prognosis include age at onset older than 40 years [29], [31], hypercalcemia [29], extrapulmonary involvement (ie, chronic eye, bone, or sarcoidosis of the upper respiratory tract
Influence of chest radiographic findings on prognosis
Although the chest radiographic staging system was developed approximately 50 years ago, currently it still has a certain prognostic value [4], [9]. Scandinavian authors emphasized the predominance of stages I and II with good prognosis among patients who have sarcoidosis in that part of the world [4]. The prognosis is best with radiographic stage I in patients who have sarcoidosis all over the world. In a study by Scadding [9], patients who had sarcoidosis were followed for 5 years. At the end
CT scans
A routine CT chest scan is not necessary in managing sarcoidosis [38]. Thoracic CT scans may be helpful in patients who have sarcoidosis and atypical chest radiographic findings or atypical clinical manifestations of the disease or in patients with normal chest radiographic findings but clinical suspicion for sarcoidosis [1], [22]. A thoracic CT scan is indicated to detect specific complications of sarcoidosis, such as bronchiectasis, aspergilloma, pulmonary fibrosis with honeycombing, and
Lung function impairments in sarcoidosis
“With no other disease did pulmonary physiologists have so much fun as with sarcoidosis. More is yet to come, because so much remains unexplained” [19], [40], [41], [42], [43]. This observation was written 20 years ago to introduce the topic on functional impairments in sarcoidosis at the Meeting of Sarcoidosis in Milan, Italy in 1988. Considering lung function in sarcoidosis, this introduction remains appropriate two decades later.
Respiratory tract involvement occurs at some time during the
Lung function impairments and prognosis of sarcoidosis
Criteria of assessing the response to therapy or the actual improvement of the lung function parameters have not been validated. Most authors define the increase of forced vital capacity of more than 10% to 15% and diffusing capacity for carbon monoxide of more than 20% as significant [4], [64], [65]. Several studies on lung function impairments in sarcoidosis showed the importance of lung function testing in following the course and assessing the response to the treatment. In these studies,
Diagnosis of pulmonary sarcoidosis
The diagnosis of pulmonary sarcoidosis is based on (1) recognizing the possible clinical manifestations of sarcoidosis, (2) recognizing the chest radiographic abnormalities, and (3) finding the histologic evidence of noncaseating granuloma. Finding the histologic evidence of noncaseating granuloma, the hallmark of sarcoidosis, requires lung biopsy procedures in patients with suspected pulmonary sarcoidosis. The initial procedure is flexible fiberoptic bronchoscopy with transbronchial lung
Pleural sarcoidosis
Pleural involvement is an uncommon manifestation of sarcoidosis. It may manifest as a pleural effusion, pneumothorax, pleural thickening and nodules, hydropneumothorax, trapped lung, hemothorax, or chylothorax [4], [70], [71], [72], [73], [74], [75], [76]. Clinically significant pleural manifestations (eg, pneumothorax, pleural effusions or chylothorax) occur in 2% to 4% of patients who have sarcoidosis [4], [70], [72], [77], [78], [79], [80], [81]. With the introduction of CT scan, especially
Pleural effusions
Pleural effusions complicate sarcoidosis in less than 3% of patients; when present, they are usually asymptomatic [4], [72]. The incidence of pleural effusion with sarcoidosis ranges from 0 to 5% [71], [72], [78] but has been reported to be as high as 7.5% [81]. An analysis of the published references up to 1985 that included reports of pleural involvement with sarcoidosis [14], [77], [78], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93], [94] showed that out of a
Pneumothorax
Pneumothorax occurs in 2% to 4% of patients who have sarcoidosis (Fig. 10) [4], [118], [119]. The necrosis of subpleural granuloma or the rupture of bullae or both seem to be the mechanism of this rare manifestation of sarcoidosis [71], [82]. Since the first description by Freiman in 1948, numerous reports have described the association between pneumothorax and sarcoidosis [14], [84], [85], [92], [93], [118], [119], [120], [121], [122], [123], [124], [125]. Pneumothorax may be the presenting
Pleural thickening and nodules
Pleural thickening is much more common in sarcoidosis than has been emphasized in the literature [4], [71], [72], [81], [82], [88], [106], [111]. It has been found often at thoracotomy [106] and autopsy. It is rarely extensive enough to produce clinical or physiologic consequences [105]. Pleural thickening is usually not associated with clinical symptoms [4], [72], [82]. Pleural thickening and abnormalities of the subpleural region have been recognized increasingly in sarcoidosis by use of
Summary
Sarcoidosis, an enigmatic multisystemic disease, has many different faces. Every patient has his or her own story, and every sarcoidologist has a unique but complex approach to maintaining the disease. Although multisystemic involvement is characteristic of the disease and virtually any organ can be affected, lungs are involved in more than 90% of patients who have sarcoidosis. Radiographic features and lung function impairments are supportive in managing how serious the disease is in an
References (142)
- et al.
Pulmonary sarcoidosis
Clin Chest Med
(1997) Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy
Chest
(2002)- et al.
Manifestations of sarcoidosis: analysis of 145 patients, with review of nine series selected from the literature
Am J Med
(1963) - et al.
Sarcoidosis of the upper lung fields simulating pulmonary tuberculosis
Chest
(1973) - et al.
Sarcoidosis and aspergilloma: the role of surgery
Chest
(1982) - et al.
Aspergilloma in sarcoid and tuberculosis
Chest
(1987) - et al.
Lofgren's syndrome revisited: a study of 186 patients
Am J Med
(1999) - et al.
Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy
Chest
(1997) - et al.
Airflow limitation in sarcoidosis: a study of pulmonary function in 107 newly diagnosed patients
Respir Med
(1991) - et al.
Interstitial lung disease: current concepts of pathogenesis, staging and therapy
Am J Med
(1981)
Early treatment of stage II sarcoidosis improves 5-year pulmonary function
Chest
Pulmonary function tests in interstitial lung disease: what role do they have?
Clin Chest Med
Airway obstruction in sarcoidosis: a study of 123 nonsmoking black American patients with sarcoidosis
Chest
Airway function in sarcoidosis
Am J Med
Airflow limitation in sarcoidosis: a study of pulmonary function in 107 patients with newly diagnosed disease
Respir Med
Bronchiolar narrowing and occlusion in sarcoidosis: correlation of pathology with physiology
Respir Med
Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis
Chest
Use of pulmonary function tests in the management of sarcoidosis
Chest
Mediastinal transthoracic needle and core lymph node biopsy: should it replace mediastinoscopy?
Chest
Superior vena cava obstruction due to sarcoidosis
Chest
Pleural involvement in sarcoidosis
Am J Med
Sarcoidosis: typical and atypical thoracic manifestations and complications
Clin Radiol
Exudative pleurisy and sarcoidosis
Br J Dis Chest
Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. Statement on sarcoidosis. February 1999
Am J Respir Crit Care Med
Sarcoidosis
N Engl J Med
Pulmonary sarcoidosis
Semin Respir Crit Care Med
Clinical characteristics of patients in a case control study of sarcoidosis
Am J Respir Crit Care Med
Two year prognosis of sarcoidosis: the ACCESS experience
Sarcoidosis Vasc Diffuse Lung Dis
The incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK
Thorax
Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation
BMJ
Sarcoidosis: epidemiology and prognosis: a 15-year European study
Am Rev Respir Dis
Sarcoidosis: clinical management
Clinical presentation and natural history of sarcoidosis
Fever of obscure origin: report of 100 cases
Medicine
Course and prognosis of sarcoidosis around the world
Am J Med
Current concepts of the pathogenesis of sarcoidosis
Am Rev Respir Dis
Atlas of sarcoidosis
Sarcoidosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests
Radiology
The relationship between alveolar macrophage, TNF, IL-1 and PGE2 release, alveolitis and disease severity in sarcoidosis
Chest
A clinical interpretation of bilateral hilar adenopathy
Ann Intern Med
Computed tomographic scanning in sarcoidosis
Semin Respir Crit Care Med
Large lung bullae in sarcoidosis
Thorax
Bullous emphysema occurring in pulmonary sarcoidosis
Respiration
Aggressive cavitary pulmonary sarcoidosis
Am Rev Respir Dis
Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients
Sarcoidosis Vasc Diffuse Lung Dis
Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients
Q J Med
Clinical courses and prognoses of pulmonary sarcoidosis
Curr Opin Pulm Med
Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases
Respiration
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment
Thorax
Outcome of the treatment for sarcoidosis
Am J Respir Crit Care Med
Cited by (40)
Sarcoidosis Lung
2018, Revue du Rhumatisme MonographiesSarcoidosis
2015, Dermatologic ClinicsCitation Excerpt :Pulmonary hypertension is a serious complication that occurs in 1% to 6% of patients overall, usually in symptomatic cases of pulmonary disease.106 About half of patients with intrathoracic sarcoidosis present with hilar adenopathy (stage I disease) that is bilateral in nearly all cases.107 In the United States and Europe, respiratory failure accounts for the largest number of sarcoidosis-related deaths.108,109
Sarcoidosis: overview of pulmonary manifestations and imaging
2015, Seminars in RoentgenologyCitation Excerpt :Although not originally included by Scadding, a “stage 0” eventually was added to the staging system and designates a radiograph without evidence of sarcoidosis.2 Approximately 8%-10% of patients with sarcoidosis have a normal radiograph finding, corresponding to stage 0.21,22 The remainder of patients have abnormal radiograph findings, with lymphadenopathy the most commonly detected abnormality (25%-65%).8
Chronic Pneumonia
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesSarcoidosis: A comprehensive review and update for the dermatologist: Part II. Extracutaneous disease
2012, Journal of the American Academy of DermatologyCitation Excerpt :More than half of patients with sarcoidosis are initially asymptomatic and have bilateral hilar lymphadenopathy (stage I) on the primary chest radiograph.17 Patients with stage IV chest radiographs usually have chronic, symptomatic pulmonary disease with irreversible fibrosis on chest radiograph,17,19 and may develop complications such as pneumothorax, cor pulmonale, mycetomas, or respiratory failure.17,19 Pulmonary function tests are abnormal in 20% of patients with stage I chest radiographs and in 40% to 70% of patients with higher stages.4
Exertional Dyspnea Incidentally Diagnosed as Sarcoidosis: A Teaching Hospital Experience
2023, Case Reports in Pulmonology